



UNIVERSITY OF
NEWCASTLE

IMMVirX

Advancing Precision Cancer Therapies Through Innovative Biotechnologies

ImmVirX is a cutting-edge oncology-focused biotechnology company that integrates innovative immune-based approaches to transform the future of cancer treatment. Building on strong research and clinical capabilities, ImmVirX develops therapies designed to enhance patients' immune responses to various cancers while delivering meaningful clinical outcomes.

PARTNERSHIP CAPABILITIES

- Early discovery and preclinical development of novel immune-based cancer therapies.
- Collaboration with leading global healthcare companies to advance clinical research.
- Expertise in complex biotechnological processes and therapeutic design.
- Investment opportunities for scaling innovation and expanding clinical trials.
- Access to advanced research facilities and experienced scientific teams for joint projects.
- Identification of biomarkers to enhance treatment precision and efficacy.
- Development of customised combination therapies tailored to specific tumour types.

PROVEN IMPACT

- Development of next-generation immuno-oncology treatments.
- Innovative combination therapies, such as ImmVirX's IVX037, in collaboration with anti-PD-1 therapy, TYVYT®.
- Potential to improve patient outcomes through the precision application of combination therapy.

BREAKTHROUGH IN IMMUNO-ONCOLOGY COLLABORATION

ImmVirX's IVX037, when paired with Innovent's anti-PD-1 therapy TYVYT®, is showing early promising signals in the clinic. These therapies play complementary roles in harnessing the immune system to combat cancer. This collaboration signifies a major milestone in next-generation immuno-oncology treatments and showcases ImmVirX's ability to deliver advanced, impactful cancer therapies.

ImmVirX 

CONTACT US:

Dr Min Quah

Director, Early Discovery and Preclinical Science

min.quah@immvirx.com

